$526 Million is the total value of BVF INC/IL's 31 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 53.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IRWD | Sell | IRONWOOD PHARMACEUTICALS INC | $78,037,000 | +7.6% | 5,093,810 | -9.0% | 15.18% | +0.8% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $55,683,000 | +12.4% | 11,772,335 | -15.2% | 10.83% | +5.3% |
| LGND | Sell | LIGAND PHARMACEUTICALS INC | $45,764,000 | -12.2% | 860,063 | -22.4% | 8.90% | -17.7% |
| FPRX | Sell | FIVE PRIME THERAPEUTICS INC | $22,311,000 | +30.1% | 826,332 | -43.5% | 4.34% | +21.9% |
| LOXO | Sell | LOXO ONCOLOGY INC | $13,991,000 | -10.6% | 1,190,702 | -0.1% | 2.72% | -16.2% |
| Sell | ARRAY BIOPHARMA INCnote 3.000% 06/0 | $8,477,000 | -41.1% | 9,000,000 | -43.8% | 1.65% | -44.8% | |
| RGDO | Sell | REGADO BIOSCIENCES INC | $1,719,000 | -41.6% | 1,882,521 | -27.8% | 0.33% | -45.4% |
| TSPT | Exit | TRANSCEPT PHARMACEUTICALS IN | $0 | – | -150,000 | -100.0% | -0.06% | – |
| PTN | Exit | PALATIN TECHNOLOGIES INC | $0 | – | -750,655 | -100.0% | -0.14% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -106,500 | -100.0% | -0.20% | – |
| RGLS | Exit | REGULUS THERAPEUTICS INC | $0 | – | -184,999 | -100.0% | -0.26% | – |
| ARDX | Exit | ARDELYX INC | $0 | – | -453,541 | -100.0% | -1.34% | – |
| TRVN | Exit | TREVENA INC | $0 | – | -1,118,743 | -100.0% | -1.49% | – |
| PRQR | Exit | PROQR THRAPEUTICS N V | $0 | – | -549,000 | -100.0% | -1.96% | – |
| RCPT | Exit | RECEPTOS INC | $0 | – | -1,146,300 | -100.0% | -14.78% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-10 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.